Ivabradine Milpharm

Ivabradine, the active ingredient in Ivabradine Milpharm, is a If channel inhibitor presented as an oral dosage form for oral use. It lowers heart rate without affecting myocardial contractility and is indicated for chronic stable angina and heart failure with reduced ejection fraction.\n\nGNH India supplies Ivabradine Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to control heart rate in specific cardiovascular conditions.\n\nChronic stable angina: reduces the frequency of angina attacks by lowering heart rate while preserving contractile function.\nHeart failure with reduced ejection fraction: improves symptoms and may decrease hospitalisation by maintaining a lower, steady heart rate.

Ivabradine is generally well tolerated, but several adverse reactions have been reported.\n\nCommon Side Effects:\n- Bradycardia: heart rate falls below the desired range.\n- Visual disturbances (phosphenes): transient luminous phenomena.\n- Headache: mild to moderate intensity.\n- Dizziness or vertigo: especially on standing.\n- Fatigue: reduced energy levels.\n\nSerious or Rare Side Effects:\n- Severe bradycardia leading to syncope.\n- Atrial fibrillation or other supraventricular arrhythmias.\n- Symptomatic hypotension with dizziness or fainting.\n- Vision loss or persistent visual impairment (rare).

Before initiating therapy, clinicians should evaluate cardiovascular status and monitor heart rate regularly.\n\nCardiovascular assessment: confirm baseline heart rate and rhythm.\nAvoid in severe sinus node dysfunction: contraindicated in patients with sick sinus syndrome.\nCaution with concomitant bradycardic agents: monitor when used with beta‑blockers or digoxin.\nHepatic impairment: dose adjustment may be required in moderate to severe liver disease.\nPregnancy and lactation: safety not established; use only if benefits outweigh risks.\nStore at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ivabradine may interact with several medicines that affect heart rate or its metabolism.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase plasma levels.\n- Other bradycardic agents (beta‑blockers, digoxin): may cause excessive heart‑rate reduction.\n- Drugs that prolong AV conduction (verapamil, diltiazem): increase risk of atrioventricular block.\n\nModerate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may require dose adjustment.\n- Antihypertensives (ACE inhibitors, ARBs): monitor blood pressure for additive effects.\n- QT‑prolonging agents: observe for any changes in cardiac repolarisation.